Success Metrics

Clinical Success Rate
93.7%

Based on 74 completed trials

Completion Rate
94%(74/79)
Active Trials
3(3%)
Results Posted
24%(18 trials)
Terminated
5(5%)

Phase Distribution

Ph not_applicable
49
51%
Ph phase_1
11
11%
Ph phase_4
3
3%
Ph early_phase_1
4
4%
Ph phase_2
22
23%
Ph phase_3
7
7%

Phase Distribution

15

Early Stage

22

Mid Stage

10

Late Stage

Phase Distribution96 total trials
Early Phase 1First-in-human
4(4.2%)
Phase 1Safety & dosage
11(11.5%)
Phase 2Efficacy & side effects
22(22.9%)
Phase 3Large-scale testing
7(7.3%)
Phase 4Post-market surveillance
3(3.1%)
N/ANon-phased studies
49(51.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

91.4%

74 of 81 finished

Non-Completion Rate

8.6%

7 ended early

Currently Active

3

trials recruiting

Total Trials

97

all time

Status Distribution
Active(4)
Completed(74)
Terminated(7)
Other(12)

Detailed Status

Completed74
unknown12
Terminated5
Withdrawn2
Recruiting2
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
97
Active
3
Success Rate
93.7%
Most Advanced
Phase 4

Trials by Phase

Early Phase 14 (4.2%)
Phase 111 (11.5%)
Phase 222 (22.9%)
Phase 37 (7.3%)
Phase 43 (3.1%)
N/A49 (51.0%)

Trials by Status

terminated55%
unknown1212%
withdrawn22%
recruiting22%
active_not_recruiting11%
not_yet_recruiting11%
completed7476%

Recent Activity

Clinical Trials (97)

Showing 20 of 97 trialsScroll for more
NCT07569744Not Applicable

Resveratrol for Endothelial Dysfunction and Metabolic Control in Type 2 Diabetes

Not Yet Recruiting
NCT06250283Not Applicable

Resveratrol for the Prevention of Bone Loss in Postmenopausal Women

Completed
NCT05377242Not Applicable

Curcumin, Resveratrol, and Stinging Nettle as Treatments for GWI

Active Not Recruiting
NCT02314208Phase 2

Therapeutic Metabolic Intervention in Patients With Spastic Paraplegia SPG5

Completed
NCT04166396Early Phase 1

Non-pulmonary Contributors of Exercise Intolerance in Patients With Cystic Fibrosis

Completed
NCT06961279Not Applicable

Resveratrol Stimulates Insulin Sensitivity in Subjects With Obesity and Insulin Resistance

Completed
NCT03436992Not Applicable

Estrogen and Diabetes

Completed
NCT04449198Early Phase 1

Type 1 Diabetes, Endothelin, and Skeletal Muscle Mitochondrial Dysfunction: The Role of Sirtuin-1

Recruiting
NCT02909686Not Applicable

Effects of Botanical Microglia Modulators in Gulf War Illness

Completed
NCT03743636Phase 3

Nicotinamide Riboside With and Without Resveratrol to Improve Functioning in Peripheral Artery Disease

Completed
NCT03597568Not Applicable

Resveratrol and Vascular Function in CKD

Completed
NCT03525379Phase 2

Evaluating the Clinical Efficacy of Resveratrol in Improving Metabolic and Skeletal Muscle Function in Patients With Heart Failure

Completed
NCT06131918Phase 2

Assessment of Antioxidant Therapy on Oxidative Stress Biomarkers in Type 2 Diabetic Patients With Neuropathy

Completed
NCT03933163Phase 2

Micronised Resveratrol as a Treatment for Friedreich Ataxia

Completed
NCT03819517Early Phase 1

Improving Cardiovascular Health in Patients With Chronic Obstructive Pulmonary Disease

Completed
NCT05653895Not Applicable

Independent and Additive Effects Of Micronutrients With Metformin In Patients With PCOS

Completed
NCT06235294Not Applicable

Effects of Resveratrol Supplementation on Oocyte Quality

Unknown
NCT05808387Not Applicable

The Effects of Resveratrol on Sirtuins and Apoptosis Biomarkers

Recruiting
NCT05172947Not Applicable

Effect of Resveratrol and Pharmacist Intervention on Diabetes Mellitus and Its Neuropathic Complication

Completed
NCT04400890Phase 2

Randomized Proof-of-Concept Trial to Evaluate the Safety and Explore the Effectiveness of Resveratrol, a Plant Polyphenol, for COVID-19

Terminated

Drug Details

Intervention Type
DRUG
Total Trials
97